PubMed articles specifically about using GLP-1 receptor agonists for weight loss. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771. PMID: 22236411. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. doi:

In-vitro is a Latin term that means “in glass” and refers to experiments or studies that are performed outside of a living organism, such as in a test tube, petri dish, or other laboratory apparatus. In-vitro research typically involves the use of isolated cells or tissues, as well as chemical or biological substances, to study biological processes or test the effects of drugs or other compounds. In-vitro research is an important part of the drug

There are several new generations of GLP-1 receptor agonists that are currently in development and applying for FDA approval. These new drugs are designed to be more effective, longer lasting, and more convenient for patients compared to currently available GLP-1 receptor agonists. One of these new drugs is known as efpeglenatide, which is a long-acting GLP-1 receptor agonist that is administered once every four weeks. In clinical trials, efpeglenatide has been shown to be effective

Semaglutide is a GLP-1 receptor agonist medication that is currently used to treat type 2 diabetes mellitus. It was first approved by the US Food and Drug Administration (FDA) in December 2017, and has since been approved in other countries around the world. The development of semaglutide began in the early 2000s, when researchers at the Danish pharmaceutical company Novo Nordisk began investigating the potential of GLP-1 receptor agonists as a treatment for type 2

GLP-1 receptor agonists are a class of medications used to treat type 2 diabetes mellitus. However, they have also been found to be effective in promoting weight loss. The exact mechanism by which GLP-1 receptor agonists promote weight loss is not fully understood, but it is thought to be due to several factors. One mechanism is through their effect on appetite. GLP-1 receptor agonists slow down gastric emptying, which means food stays in the stomach